EUVIMEDEUVIMED entdecken
Crossref

Treatment outcomes and prognostic factors in children with hepatoblastoma using a risk‐stratified approach

Shyam Srinivasan iD, Maya Prasad iD, Badira C Parambil iD, Anurag Shrimal iD, Venkata Rama Mohan Gollamudi, Vignesh Subramani, Mukta Ramadwar, Nehal Khanna, Akshay D Baheti, Kunal Gala, Vasundhara Patil, Siddhartha Laskar iD und 2 weitere

Pediatric Blood & Cancer · 2023-07 · 70 (7)

DOI: 10.1002/pbc.30302 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 12.04.2023. Verfasst von Shyam Srinivasan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India. Hauptthemen laut MEDLINE: Hepatoblastoma, Liver Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Not all the significant progress made in the management of children with hepatoblastoma (HB) has translated into improved outcomes in limited‐resource settings. There are limited data on outcomes in children with HB from India.

Methods

All patients diagnosed with HB between July 2013 and December 2020 were risk‐stratified and treated as per International Liver Tumor Strategy Group (SIOPEL). Patients with standard‐risk HB received cisplatin monotherapy and those with high‐risk HB received alternating cycles of cisplatin and the combination of carboplatin plus doxorubicin. Data regarding demographic details, chemotherapy, surgery, liver transplantation, outcomes, prognostic factors, and toxicity were collected.

Results

Of 157 patients with HB, 117 (74%) were high risk, 31 (20%) were standard risk, and nine (6%) unknown. Patients with standard‐risk disease had excellent outcomes, with 3‐year event‐free survival (EFS) and overall survival (OS) of 96% and 100%, respectively. Among high‐risk HB, six underwent orthotopic liver transplantation of which four were alive at last follow‐up. The 3‐year EFS and OS of patients with high‐risk disease was 56% and 66%, respectively. Outcomes of patients with PRETEXT IV (3‐year EFS: 42%, 3‐year OS: 50%) and metastatic disease (3‐year EFS: 30%, 3‐year OS: 50%) were dismal. Patients with serum alpha‐fetoprotein (AFP) reduction greater than 90% following two courses of chemotherapy had favorable outcomes; 3‐year EFS: 80% versus 58% ( p = .013) and 3‐year OS: 95% vs. 68% ( p < .01). Only two (6%) of 31 patients with relapse/refractory HB were alive at a median follow‐up of 36 months, and both had received salvage chemotherapy and surgery.

Conclusions

While children with standard‐risk HB had excellent outcomes, those with high‐risk disease continue to do poorly. Serial monitoring of serum AFP values is a cost‐effective and reliable predictor of outcomes. Orthotopic liver transplantation remains a viable option for inoperable disease in resource‐limited settings as well.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HepatoblastomaLiver NeoplasmsChildHumansInfantCisplatinPrognosisalpha-FetoproteinsAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalTreatment OutcomeCarboplatinDoxorubicin

Stichwörter der Autor:innen

Indiaalpha-fetoproteinhepatoblastomaliver transplantationsurvival

Substanzen

Cisplatinalpha-FetoproteinsCarboplatinDoxorubicin

Autor:innen und Institutionen

  • Division of Pediatric Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
  • Institute of Liver, Pancreas & Intestine Transplantation, Dr Balabhai Nanavati Hospital, Mumbai, Maharashtra, India.
  • Department of Pathology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
  • Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
  • Department of Radiodiagnosis, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
  • Department of Pediatric Surgery, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India.

ORCID-Profile: Shyam Srinivasan, Maya Prasad, Badira C Parambil, Anurag Shrimal, Siddhartha Laskar, Sajid Qureshi

Zitieren

APA

Srinivasan, S., Prasad, M., Parambil, B. C., Shrimal, A., Gollamudi, V. R. M., Subramani, V., Ramadwar, M., Khanna, N., Baheti, A. D., Gala, K., Patil, V., Laskar, S., Qureshi, S., & Chinnaswamy, G. (2023). Treatment outcomes and prognostic factors in children with hepatoblastoma using a risk‐stratified approach. Pediatric Blood & Cancer, 70(7). https://doi.org/10.1002/pbc.30302

Vancouver

Srinivasan S, Prasad M, Parambil BC, Shrimal A, Gollamudi VRM, Subramani V, et al. Treatment outcomes and prognostic factors in children with hepatoblastoma using a risk‐stratified approach. Pediatric Blood & Cancer. 2023;70(7). doi:10.1002/pbc.30302

BibTeX
@article{Srinivasan2023,
  author = {Srinivasan, Shyam and Prasad, Maya and Parambil, Badira C and Shrimal, Anurag and Gollamudi, Venkata Rama Mohan and Subramani, Vignesh and Ramadwar, Mukta and Khanna, Nehal and Baheti, Akshay D and Gala, Kunal and Patil, Vasundhara and Laskar, Siddhartha and Qureshi, Sajid and Chinnaswamy, Girish},
  title = {Treatment outcomes and prognostic factors in children with hepatoblastoma using a risk‐stratified approach},
  journal = {Pediatric Blood & Cancer},
  year = {2023},
  volume = {70},
  number = {7},
  doi = {10.1002/pbc.30302}
}
Kostenlos starten →